Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients

https://doi.org/10.14412/2074-2711-2016-2-17-23

Abstract

Objective: to evaluate the efficacy of Tanakan® (EGB761®) used in young and middle-aged patients with mixed cognitive impairments (CI) and emotional diseases.

Patients and methods. An open-label observational study of the efficacy of Tanakan® was conducted in 54 patients aged 18–4 years with CI and psychoemotional disorders. Tanakan® was administered at a daily dose of 120 mg (40 mg t.i.d) for 3 months.

Results. Tanakan® therapy resulted in health improvement, as shown by the HAM (Health, Activity, Mood) questionnaire; the mean score of the latter increased from 3.86 at baseline to 4.84 after 3 months of treatment. There were improvements in three HAM questionnaire items: the mean score of the item «Health» increased from 3.69 to 4.79; that of the item «Activity» from 3.65 to 4.58, and that the item «Mood» from 4.25 to 5.14 after the completion of the investigation.

Tanakan® therapy also demonstrated improvements in memory (the mean number of correctly repeated words increased from 5.7 to 6.7 at the beginning of a visit and from 4.2 to 5.8 at its end) and in attention (the mean symbol-digit coding test score increased from 48.1 to 55.7%. There were no clinically relevant differences between patients with higher and secondary education in the efficacy of Tanakan®.

Conclusion. Tanakan® had a very good safety profile; no adverse drug events were recorded during the investigation. Almost all the 53 (98.1%) of the 54 patients were satisfied with Tanakan® therapy results after 3 months of treatment. 

About the Authors

V. A. Parfenov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Neurology and Neurosurgery

11, Rossolimo St., Moscow 119021



E. Yu. Solovyeva
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation

Department of Neurology

1, Ostrovityanov St., Moscow 117997



L. M. Antonenko
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Neurology and Neurosurgery

11, Rossolimo St., Moscow 119021



A. B. Lokshina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Neurology and Neurosurgery

11, Rossolimo St., Moscow 119021



T. Gorskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation

Department of Neurology and Neurosurgery

11, Rossolimo St., Moscow 119021



References

1. Преображенская ИС. Легкие и умеренные когнитивные нарушения – клинические проявления, этиология, патогенез, возможности использования ноотропной терапии. Фарматека. 2013;(s4-13):14-8. [Preobrazhenskaya IS. Light and moderate cognitive disorders – clinical manifestations, etiology, pathogenesis, the possibility of using nootropic therapy. Farmateka. 2013;(s4-13): 14-8. (In Russ.)].

2. Филатова ЕГ, Наприенко МВ. Терапия нарушений памяти и внимания у молодых пациентов. Неврология, нейропсихиатрия, психосоматика. 2013;5(3):18–23. [Filatova EG, Naprienko MV. Therapy for memory and attention impairments in young patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2013;5(3):18–23. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711- 2013-2334

3. Balash Y, Mordechovich M, Shabtai H, et al. Subjective memory complaints in elders: depression, anxiety or cognitive decline? Acta Neurol Scand. 2013 May;127(5):344-50. doi: 10.1111/ane.12038. Epub 2012 Dec 6.

4. Grass-Kapanke B, Busmane A, Lasmanis A, et al. Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI). Neuroscience & Medicine. 2011;(2):48-56.

5. Aasvik JK, Woodhouse A, Jacobsen HB, et al. Subjective memory complaints among patients on sick leave are associated with symptoms of fatigue and anxiety. Front Psychol. 2015 Sep 8;6:1338. doi: 10.3389/fpsyg.2015.01338. eCollection 2015.

6. Castaneda AE. Cognitive Functioning in Young Adults with Depression, Anxiety Disorders, or Burnout Symptoms. Findings from a Population-based Sample. Academic dissertation. Helsinki, 2010.

7. Brondino N, De Silvestri A, Re S, et al. A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Evid Based Complement Alternat Med. 2013;2013:915691. doi: 10.1155/2013/915691. Epub 2013 May 28.

8. DeFeudis FV, Drieu K. Ginkgo Biloba Extract (EGb 761®) and CNS Functions: Basic Studies and Clinical Applications. Curr Drug Targets. 2000 Jul;1(1):25-58.

9. Cieza A, Maier P, Pö ppel E. The effect of ginkgo biloba on healthy elderly subjects. Fortschr Med Orig. 2003;121(1):5-10.

10. Von Gunten A, Schlaefke S, Überla K. Efficacy of Ginkgo biloba extract (EGb 761®) in dementia with behavioural and psychological symptoms: A systematic review. World J Biol Psychiatry. 2015 Aug 27:1-12. [Epub ahead of print]

11. Gavrilova SI, Preuss UW, Wong JW, et al. Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multicenter trial. Int J Geriatr Psychiatry. 2014 Oct;29(10): 1087-95. doi: 10.1002/gps.4103. Epub 2014 Mar 16.

12. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, doubleblind, placebo-controlled trial. J Psychiatr Res. 2007 Sep;41(6):472-80. Epub 2006 Jun 30.

13. Jezova D, Duncko R, Lassanova M, et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGB 761®) in healthy volunteers. J Physiol Pharmacol. 2002 Sep;53(3):337-48.

14. Краснов ВН, Вельтищев ДЮ. Неврастения как вариант астенического синдрома: фармакотерапевтический анализ на модели терапии Tанаканом. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;99(7):37-40. [Krasnov VN, Vel'tishchev DYu. Neurasthenia as a variant of the asthenic syndrome: pharmacological analysis of a model of therapy with Tanakan. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1999;99(7):37-40. (In Russ.)].

15. Милопольская ИМ. Лечение Танаканом астенических расстройств. Терапевтический архив. 2001;73(10):45-7. [Milopol'skaya IM. Treatment of asthenic disorders with Tanakan. Terapevticheskii arkhiv. 2001;73(10):45-7. (In Russ.)].

16. Незнамов ГГ, Телешова ЕС, Сюняков СА и др. Влияние танакана на психофизиологическое состояние больных с астеническими расстройствами. Экспери- ментальная и клиническая психофармако- логия. 2002;65(1):22-8. [Neznamov GG, Teleshova ES, Syunyakov SA, et al. Effect of tanakan on the psychophysiological state of patients with asthenic disorders. Eksperimental'naya i klinicheskaya psikhofarmakologiya. 2002;65(1):22-8. (In Russ.)].

17. Незнамов ГГ, Сюняков СА, Давыдова ИА, Телещова ЕС. «Быстрые» и «медленные» компоненты психотропного действия препаратов с ноотропными свойствами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2000;100(6):33-7. [Neznamov GG, Syunyakov SA, Davydova IA, Teleshchova ES. «Fast» and «slow» components of psychotropic action of drugs with nootropic properties. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2000;100(6):33-7. (In Russ.)].

18. Незнамов ГГ, Давыдова ИА, Кошелев ВВ и др. Перспективы применения Танакана в качестве антиастенического средства. Социальная и клиническая психиатрия. 1999;(2):21-6. [Neznamov GG, Davydova IA, Koshelev VV, et al. Prospects for the use of Tanakan as antiasthenic drug. Sotsial'naya i klinicheskaya psikhiatriya. 1999;(2):21-6. (In Russ.)].

19. Применение танакана в психиатрической и наркологической практике. Информационное письмо Министерства здравоохранения Российской Федерации № 19-04/ 6-105 от 14.04.1999. С. 2-21. [The use of tanakan in psychiatric and narcologic treatment. Information letter of the Ministry of health of the Russian Federation No. 19-04/ 6-105 from 14.04.1999. P. 2-21]

20. Доскин ВА, Лаврентьева НА, Мирошников МП, Шарай ВБ. Тест дифференцированной самооценки функционального состояния. Вопросы психологии. 1973;(6):141-5. [Doskin VA, Lavrent'eva NA, Miroshnikov MP, Sharai VB. Test of differentiated self-assessment of functional status. Voprosy psikhologii. 1973;(6):141-5. (In Russ.)].

21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.

22. Kaschel R. Specific memory effects of Ginkgo biloba extract EGB 761 in middle-aged healthy volunteers. Phytomedicine. 2011 Nov 15;18(14):1202-7. doi: 10.1016/j.phymed.2011. 06.021. Epub 2011 Jul 30.


Review

Views: 782


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)